Navigation Links
Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds

SAN DIEGO, Oct. 30, 2012 /PRNewswire/ -- Thesan Pharmaceuticals announced the closing of a $16M Series A financing, co-led by Novo Ventures and Novartis Venture Funds.  The company will focus on the development of novel approaches for the treatment of dermatological disorders. The lead drug candidate is a topically-applied new chemical entity expected to enter the clinic in 2013.

"For many years, drug development in the dermatology field has been dominated by old drugs just re-formulated into more cosmetically appealing foams, gels or lotions," said Gordon Foulkes, Thesan's Executive Chairman and CEO. "Thesan's mission is to develop new chemical entities with novel mechanisms of action in order to substantially improve treatment outcomes for patients with a variety of dermatological diseases." 

The company's first products have been licensed from the University of California, Irvine (UCI). The products have been developed in the laboratory of Professor Daniele Piomelli, who is Louise Turner Arnold Chair of Neurosciences at UCI and the Director of Drug Discovery and Development at the Istituto Italiano di Tecnologia (IIT), Genoa, Italy.  

"We are very pleased to be part of the investor syndicate behind Thesan," said Peter Bisgaard, Partner at Novo Ventures. "We believe Professor Piomelli's work offers a unique opportunity for developing a completely new class of anti-inflammatory agents, which can be moved rapidly into clinical development. Further, we look forward to working with Professor Piomelli and Thesan management to build the pipeline of future candidates."

"This is an extremely exciting opportunity to move toward the clinic the first technology born from the long-standing international collaboration between UCI and the IIT," said Professor Piomelli. "Our collaboration to develop therapeutic candidates has been validated by our ability to attract such a strong management team and group of investors to further commercialize our laboratories' efforts."

"A novel mechanism of action with dramatic efficacy, coupled with such solid chemistry is a great starting point for the formation of a new company," said Giovanni Ferrara, Venture Partner at Novartis Venture Funds.  "Combined with a world class team, it made for a compelling investment." 

In connection with the financing, Peter Bisgaard and Tiba Aynechi from Novo, as well as Giovanni Ferrara and Henry Skinner from Novartis have joined the company's Board, along with Dr. Howard Welgus, former VP R&D for Dermatology/Inflammation at Pfizer.  

About Thesan Pharmaceuticals, Inc.

Thesan is a newly formed, venture capital-funded biotechnology company focused on the development and commercialization of novel drugs for the treatment of dermatological conditions. For more information visit:

About Novo Ventures

Novo is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. It was established in 1999 to manage the assets of the foundation and actively make investments on its behalf. Novo Ventures focuses on life sciences venture capital, and is active in both Europe and North America. The firm has four partners in Copenhagen, one in London and three in San Francisco. With an evergreen structure, it annually invests approximately $100M in venture capital into private life sciences companies. For more information, visit:

About Novartis Venture Funds

Founded in 1996, the Novartis Venture Funds currently manage over $800 million in committed capital. As a financially driven corporate life science investor, the Novartis Venture Funds invest in those companies which have the potential to address significant unmet medical needs critical to patient care. The Novartis Venture Funds' team of ten investment professionals located in Basel Switzerland and Cambridge, MA brings together extensive expertise in the biotechnology, pharmaceutical and venture capital industries. For more information, visit:

About UCI

Located in the heart of Orange County, UCI is among the fastest-growing University of California campuses, is a member of the prestigious Association of American Universities (AAU), and is consistently ranked among the nation's best universities, public and private.  The Office of Technology Alliances at UCI manages over 900 active university inventions and has licensed founding technologies to more than 50 startup companies.

About IIT

The Istituto Italiano di Tecnologia is a private law Foundation jointly established by the Ministry of Education, University and Research and the Ministry of Economy and Finance, with the aim of promoting excellence in both basic and applied research and to facilitate the development of the national economy. IIT's total staff is comprises of over 1000 individuals. In Genoa, the collaborating departments include Robotics ("Robotics, Brain and Cognitive Sciences and "Advanced Robotics"), "Neuroscience and Brain Technologies; "Drug Discovery and Development" and Nanotechnology.   

J. Gordon Foulkes, Ph.D.
Chairman and Chief Executive Officer
Thesan Pharmaceuticals, Inc.

SOURCE Thesan Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
2. Neuraltus Pharmaceuticals Announces Phase 2 Clinical Results for NP001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
3. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2012 Financial Results On November 5, 2012
4. Jazz Pharmaceuticals Announces Date to Release Third Quarter 2012 Results
5. Watson Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals, a division of The Harvard Drug Group, LLC
6. Del Mar Pharmaceuticals Expands Collaboration with Guangxi Wuzhou Pharmaceutical Company
7. Webcast Alert: Isis Pharmaceuticals Third Quarter 2012 Financial Results Conference Call
8. BioMed Realty Announces 80,500 Square Foot Lease Expansion For Regeneron Pharmaceuticals
9. Access Pharmaceuticals Announces Private Placement Financing
10. Desitin Pharmaceuticals selecciona Veeva CRM, solución basada en la nube
11. Desitin Pharmaceuticals entscheidet sich für das cloudbasierte Veeva CRM zur Unterstützung seiner Expansion auf den britischen Markt
Post Your Comments:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... Rhinebeck, NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of ... of companies that call for a minimum wage raise to $12 an hour by 2020 ... wage. This will restore the lost value of the minimum wage, assure the wage floor ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):